Felix Carl Saalfeld

1. ILLINI, Oliver, SAALFELD, Felix Carl, CHRISTOPOULOS, Petros, DURUISSEAUX, Michaël, VIKSTRÖM, Anders, PELED, Nir, DEMEDTS, Ingel, DUDNIK, Elizabeth, EISERT, Anna, JANŽIČ, Urška, MOHORČIČ, Katja, IVANOVIĆ, Marija, HASHEMI, Sayed M. S., et al. Mobocertinib in patients with EGFR exon 20 insertion-positive non-small cell lung cancer (MOON) : an international real-world safety and efficacy analysis. International journal of molecular sciences. 2024, vol. 25, iss. 7, [article no.] 3992, str. 1-19, ilustr. ISSN 1422-0067. https://www.mdpi.com/1422-0067/25/7/3992, DiRROS - Digitalni repozitorij raziskovalnih organizacij Slovenije, DOI: 10.3390/ijms25073992. [COBISS.SI-ID 192029955]

2. JANŽIČ, Urška, ILLINI, Oliver, ZLATANOVA, T., ARABADJIEV, J., JAKOPOVIĆ, Marko, FOTOPOULOS, G., VALTER, A., SAALFELD, Felix Carl, WERMKE, M., HENDRIKS, Lizza E. L., et al. Access to novel therapies for the treatment of NSCLC in 18 EU member states. V: 2025 World Conference on Lung Cancer : 6-9 September 2025, Barcelona, Spain. New York: Elsevier, 2025. Str. 223-224. Journal of thoracic oncology (Online), vol. 20, issue 10, suppl. 1. ISSN 1556-1380. https://www.sciencedirect.com/science/article/abs/pii/S1556086425014649, DOI: 10.1016/j.jaip.2025.10.018. [COBISS.SI-ID 255687171]

3. SAALFELD, Felix Carl, LESSMANN, Marie-Elisabeth, RUGE, Lea, ILLINI, Oliver, KAUFFMANN-GUERRERO, Diego, MINUTH-FUCHS, Kaija, RITTMEYER, Achim, GOETTING, Isabell, SCHILDKNECHT, Katharina, MOHORČIČ, Katja, et al. Rare ALK: clinical characteristics and efficacy of targeted therapy in NSCLC with ALK fusions other than EML4::ALK = Felix Carl Saalfeld ... [et al.]. V: 2025 ASCO Annual Meeting I. Alexandria: American Society of Clinical Oncology (ASCO), 2025. Vol. 43, no. 16, suppl., str. 8625. Journal of clinical oncology (Online), Vol. 43, issue 16, suppl., 1 Jun. 2025. ISSN 1527-7755. https://ascopubs.org/doi/pdf/10.1200/JCO.2025.43.16_suppl.8625, https://www.asco.org/abstracts-presentations/ABSTRACT497258. [COBISS.SI-ID 240849667]